U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Topically applied idebenone-containing agent with protective and regenerative effect

Patent 6756045 Issued on June 29, 2004. Estimated Expiration Date: Icon_subject May 19, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Method of and composition for preventing sunburn while affording tanning
Patent #: 4144325
Issued on: 03/13/1979
Inventor: Voyt

Skin treatment methods
Patent #: 4248861
Issued on: 02/03/1981
Inventor: Schutt

Method for therapy of ischemic disease
Patent #: 4436753
Issued on: 03/13/1984
Inventor: Imada ,   et al.

Nerve growth factor secretion inducing composition
Patent #: 5059627
Issued on: 10/22/1991
Inventor: Goto, et al.

Pharmaceutical composition for treatment of dementia
Patent #: 5916925
Issued on: 06/29/1999
Inventor: Higuchi, et al.

Animal models of human amyloidoses
Patent #: 5958883
Issued on: 09/28/1999
Inventor: Snow

Use of retinoids to treat high blood pressure and other cardiovascular disease
Patent #: 6437003
Issued on: 08/20/2002
Inventor: Roullet, et al.

Nutritional supplement for cerebral metabolic insufficiencies Patent #: 6537969
Issued on: 03/25/2003
Inventor: Blass

Inventors

Application

No. 10030842 filed on 05/19/2000

US Classes:

424/401, Cosmetic, antiperspirant, dentifrice424/78.03, Skin cosmetic coating514/675, Ketone DOAI514/763, Carbocyclic514/845Liquid make-up

Examiners

Primary: Wang, Shengjun

Attorney, Agent or Firm

Foreign Patent References

  • 3049039 DE 03/01/1984
  • 0788793 EP 08/01/1997
  • 01279818 JP 11/01/1989
  • 4099719 JP 03/01/1992
  • 4099719 JP 08/01/1992
  • 11116470 JP 04/01/1999
  • 9420068 WO 09/01/1994
  • 9907355 WO 02/01/1999

International Classes

A61K 700
A61K 3174
A61K 3112
A61K 31015
A01N 2500

Claims




What is claimed is:

1. A method for treating a skin change comprising applying a topical preparation to the skin, the preparation comprising an amount of an agent effective for treating the skin change, the agent comprising idebenone, a derivative of idebenone, or a combination of idebenone and the derivative of idebenone.

2. The method as recited in claim 1 wherein the skin change includes an aging of the skin.

3. The method as recited in claim 1 wherein the skin change includes a wrinkling of the skin.

4. The method as recited in claim 1 wherein the skin change includes a damage of the skin by ultraviolet light.

5. The method as recited in claim 1 wherein the skin change includes an oxidative process.

6. The method as recited in claim 1 wherein the skin change includes a degenerative process.

7. The method as recited in claim 1 wherein the agent acts as an antioxidant.

8. The method as recited in claim 1 wherein the agent acts as a radical scavenger.

9. The method as recited in claim 1 wherein the agent acts as a stabilizer of skin cells.

10. The method as recited in claim 1 wherein the agent acts as a stabilizer of mitocondria membranes of skin cells.

11. The method as recited in claim 1 wherein the agent supports cellular respiration of skin cells so as to promote regeneration of the cells.

12. The method as recited in claim 1 wherein the agent protects the skin upon damage to the skin using an anti-apoptotic property of the respective idebenone, a derivative of idebenone, or a combination of idebenone and a derivative of idebenone.

13. The method as recited in claim 1 wherein the derivative of idebenone is a hydrophilic ester of idebenone.

14. The method as recited in claim 1 wherein the derivative of idebenone is a sulfonic acid ester of idebenone.

15. The method as recited in claim 1 wherein the derivative of idebenone is at least one of an ester of idebenone and an ester of the derivative of idebenone.

16. The method as recited in claim 1 wherein the topical preparation further comprises at least one of a glycosaminoglycan, a derivative of a glycosaminoglycan and a hyaluronidase inhibitor.

17. The method as recited in claim 1 wherein the topical preparation further comprises a cosmetic auxiliary.

18. The method as recited in claim 1 wherein the agent stabilizes another component of the preparation.

19. The method as recited in claim 18 wherein the other component includes at least one of vitamin A, a derivative of vitamin A, vitamin B, a derivative of vitamin B, vitamin C, a derivative of vitamin C, vitamin E, a derivative of vitamin C, hyaluronic acid and a derivative of hyaluronic acid.

20. The method as recited in claim 19 wherein the at least one of hyaluronic acid and a derivative of hyaluronic acid has a molecular weight of up to 1,000,000.

21. The method as recited in claim 1 wherein the topical preparation further comprises another antioxidant.

22. The method as recited in claim 1 wherein the agent protects another component of the preparation from an oxidation process.

23. The method as recited in claim 1 wherein the preparation further comprises at least one ultraviolet filter.

24. The method as recited in claim 1 wherein the preparation includes an emulsion.

25. The method as recited in claim 1 wherein the preparation includes a gel.

26. The method as recited in claim 1 wherein the idebenone, a derivative of idebenone, or a combination of idebenone and a derivative of idebenone has a concentration of from about 0.0001 to about 30% by weight of the preparation.

27. The method as recited in claim 1 wherein idebenone, a derivative of idebenone, or a combination of idebenone and a derivative of idebenone has a concentration of from about 0.05 to about 5% by weight of the preparation.

28. The method as recited in claim 1 wherein the idebenone, a derivative of idebenone, or a combination of idebenone and a derivative of idebenone has a concentration of from about 0.1 to about 2.0% by weight of the preparation.

29. The method as recited in claim 1 wherein the preparation is a cosmetic preparation.

30. The method as recited in claim 1 wherein the preparation is a dermatological preparation.

31. A method for treating a skin change comprising:

providing a person in need of treatment of the skin change, the skin change being responsive to an application of idebenone, a derivative of idebenone, or a combination of idebenone and the derivative of idebenone; and

applying an amount of the idebenone, the derivative of idebenone, or the combination of idebenone and the derivative of idebenone, effective for treating the skin change.

32. The method as recited in claim 31 wherein the skin change includes an aging of the skin.

33. The method as recited in claim 31 wherein the skin change includes a wrinkling of the skin.

34. The method as recited in claim 31 wherein the skin change includes an oxidative process.

35. The method as recited in claim 31 wherein the skin change includes a degenerative process.

36. The method as recited in claim 31 wherein the applying is included in a cleansing of the skin.

37. The method as recited in claim 31 wherein the applying is included in a cosmetic treatment of the skin.

38. A method for protecting a component of a topical skin preparation from an oxidation process, the method comprising including an amount of idebenone, a derivative of idebenone, or a combination of idebenone and the derivative of idebenone effective to protect the component from the oxidation process.

39. The method as recited in claim 13 wherein the topical skin preparation further comprises at least one compound selected from the group consisting of an alpha-hydroxy acid, vitamin A and a vitamin A derivative.

40. The method as recited in claim 39 wherein the alpha-hydroxy acid is at least one of citric acid, lactic acid, malic acid and mandelic acid.

41. The method as recited in claim 39 wherein the at least one compound has a concentration of from about 0.0001 to about 30% by weight of the preparation.

42. The method as recited in claim 41 wherein the at least one compound has a concentration of from about 0.05 to about 20% by weight of the preparation.

43. The method as recited in claim 42 wherein the at least one compound has a concentration of about 1 to about 10% by weight of the preparation.

44. The method as recited in claim 39 wherein the at least one compound is selected from the group consisting of vitamin A and a vitamin A derivative, the at least one compound having a concentration of from about 0.0001 to about 10% by weight of the preparation.

Other References

  • Machine Translation of JP 11-116470 (Apr. 27, 1999), Igari et al.*
  • Schaffler et al. “Dose-effect Relationship of Idebenone in an Experimental Cerebral Deficit Model” 1998, pp. 720-726, in Arzneim.-Forsch. / Drug. Res. Nr. 7 Abstract.
  • Schuetz et al. “Suppression of Leukocyte-Enhanced Cold Ischemia/Reperfusion Injury of Liver Endothelium with the Benzoquinone Antioxidant Idebenone” Dec., 1997, pp. 619-624, in Clinical Biochemistry, vol. 30.
  • Wieland et al. “Lipid hydroperoxide determination in serum by HPLC and iodometry” 1992, pp. 62-63, in Fresenius J. Anal Chem.
  • Michiels et al. “Cytotoxity of linoleic acid peroxide, malondialdahyde and 4-hydroxynonenal towards human fibroblasts” 1991, pp. 225-234, in Toxicology.
  • Deflandre et al. “Photostbility assessment of sunscreens. Benzylidene camphor and dibenzoylmethane derivatives” 1988, pp. 53-62, in International Journal of Cosmetic Science.
  • Yoshiki Miyachi “Skin diseases associated with oxidative injury” in Chapter 16 of “Oxidative Stress in Dermatology” 1993, pp. 323-331.
  • Thiele et al. “Depeltion of Human Stratum Corneum Vitamin E: An Early and Sensitive In Vivo Marker of Induced Photo-Oxidation” 1998, pp. 756-761, in The Journal of Investigative Dermatology.
  • Barkworth et al. “An Early Phase I Study to Determine th Tolerance, Safety and Pharmacokinetics of Idebone Following Multiple Oral Doses” 1985, pp. 1704-1707, in Arzneim.-Forsch./Drug Res. 1985.
  • Voelckel et al. “Vorkommen und Phot-Isomerisierung der Urocansaeure im stratum corneum bei polymorpher Lichtdermatose (PLD) Vergleichende Untersuchung bei PLD-Patienten und Hautgesunden” 1989, pp. 1-15, in Zentralblatt Haut- und Geschlechtskrankheiten (see application text for English description) Abstract.
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
PatentsPlus: add to cart
PatentsPlus: add to cartIntelligent turbocharged patent PDFs with marked up images
$16.95more info
 
Sign InRegister
Username  
Password   
forgot password?